ArticleScientific reports2025
Quantitative 3D assessment of muscle dystrophy through X-ray phase-contrast tomography.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Duchenne muscular dystrophy (DMD) is characterized by progressive skeletal muscle degeneration and weakness. DMD is the most common muscular dystrophy; commonly diagnosed in childhood, it has a deadly outcome, typically for respiratory or cardiac failure. In spite of a longer disease course, obtained in recent years thanks to palliative pharmacological treatments, DMD remains one of the foremost public health challenges. The intricate interaction between dysfunctional skeletal muscle fibers and the resident different cell types, including inflammatory and fibroadipogenic progenitors, directly contributes to the progression of the disease, affecting its severity. In this study, we used the remarkable precision of X-ray phase-contrast tomography (XPCT) to conduct an unprecedented three-dimensional (3D) examination of skeletal muscle architecture, comparing healthy and dystrophic mdx mice. The morphological features observed in XPCT images were compared to conventional histological sections, corroborated by morphometric evaluation of bidimensional parameters. Through XPCT, we followed the spatial disposition of degenerating or distorted dystrophic myofibers along a length of approximately 1.3 mm. In addition, the exploitation of micro-XPCT, unveiled significant quantitative differences between healthy and mdx muscles in numerous 3D parameters, such as myofiber length, variability in myofiber caliber, myofiber volume, and the volume of interstitial tissues and cells. We propose XPCT as a novel imaging tool for the ex vivo characterization of the fine architecture of dystrophic muscles: this approach is particularly relevant to highlight the outcomes of a treatment in pre-clinical models and provides the structural bases underlying the functional features of the diseased skeletal muscle.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.